Neocardio Diagnostics Llp - Company Profile

It is a healthcare limited liability partnership based in Chennai, Tamil Nadu, India, established in 2020.
2020 Chennai, Tamil Nadu, India Struck Off
Last Updated:
Access Report
About Neocardio Diagnostics Llp

Neocardio Diagnostics Llp, a struck off limited liability partnership, was established on 22 May 2020 in Chennai, Tamil Nadu, India. Engaging in medical & laboratory equipment within the healthcare sector, it holds LLPIN: AAS-4657. Registered under ROC Roc Chennai. It has total obligation of contribution of ₹1.75 Cr.

Its leadership includes Karthik Anand Reddy (Designated Partner), Sankaranarayanan Muthu Krishnan (Designated Partner), Adarsh Jalan (Partner). Its latest date of accounts and solvency statement 31 March 2021. It is based at 3Rd Floor, Jhaver Plaza 1A, Nungambakkam High Road Nungambakkam, Chennai, Tamil Nadu, 600034.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    AAS-4657

  • Incorporation Date

    22 May 2020

  • Total Obligation of Contribution

    ₹1.75 Cr

  • ROC Code

    Roc Chennai

  • Company Status

    Struck Off

Key Metrics
  • Obligation of Contribution ₹ 1.75 Cr
  • Company Age 5 Year, 8 Months
  • Last Filing with ROC 31 Mar 2021
Company report

Neocardio Diagnostics Llp

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Neocardio Diagnostics Llp — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report Banner Element
Who are the key members and board of directors at Neocardio Diagnostics Llp?
Current Designated Partners
Name Designation Appointment Date Status
Karthik Anand Reddy Designated Partner 22 May 2020 Current
Sankaranarayanan Muthu Krishnan Designated Partner 22 May 2020 Current
Adarsh Jalan Partner 22 May 2020 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Neocardio Diagnostics Llp.

Enhance accessibility to Neocardio Diagnostics Llp's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Neocardio Diagnostics Llp revenue growth over time
Neocardio Diagnostics Llp profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Neocardio Diagnostics Llp?

Unlock access to Neocardio Diagnostics Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Neocardio Diagnostics Llp?

Unlock and access historical data on people associated with Neocardio Diagnostics Llp, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Neocardio Diagnostics Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neocardio Diagnostics Llp's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Neocardio Diagnostics Llp
Recent Activity within the Organization
  • Annual General Meeting

    The activity Neocardio Diagnostics Llp last Annual general meeting of members was held on 31 Mar 2021 as per latest MCA records. was completed.

  • Statement of Assets & Liabilities

    Neocardio Diagnostics Llp has filed its annual Financial statements for the year ended 31 Mar 2021 with Roc Chennai. was recorded as a recent event.

  • Director Appointment

    The activity Karthik Anand Reddy was appointed as a Designated Partner was appointed as a Designated Partner on 22 May 2020 & has been associated with this company since 5 years 8 months . was completed.

  • Director Appointment

    The activity Sankaranarayanan Muthu Krishnan was appointed as a Designated Partner was appointed as a Designated Partner on 22 May 2020 & has been associated with this company since 5 years 8 months . was completed.

  • Director Appointment

    The activity Adarsh Jalan was appointed as a Partner was appointed as a Partner on 22 May 2020 & has been associated with this company since 5 years 8 months . was completed.

  • LLP Incorporation

    The activity Neocardio Diagnostics Llp was registered on 22 May 2020 with Roc Chennai & aged 5 years 8 months as per MCA records. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the LLPIN of Neocardio Diagnostics Llp?

The LLPIN of Neocardio Diagnostics Llp is AAS-4657.

Where is Neocardio Diagnostics Llp headquartered?

Neocardio Diagnostics Llp is headquartered at 3Rd Floor, Jhaver Plaza 1A, Nungambakkam High Road Nungambakkam, Chennai, Tamil Nadu, 600034.

When was Neocardio Diagnostics Llp incorporated?

Neocardio Diagnostics Llp was incorporated on 22 May 2020.

Who are the current directors of Neocardio Diagnostics Llp?

The current directors of Neocardio Diagnostics Llp are

What is the primary industry of Neocardio Diagnostics Llp?

The primary industry of Neocardio Diagnostics Llp is Healthcare.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available